Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | CBX7 | O95931 | 2/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.43 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 2/20 | 0.43 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.40 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203507 | 0.83 | PTPN1 (0.70) | PTPN1GSK3BCYP3A4DHODHCBX7 | |
| SCHEMBL1054478 | 0.81 | GSK3B (0.52) | PTPN1GSK3BCYP3A4DHODHCBX7 | |
| SCHEMBL12620004 | 0.81 | PTPN1 (0.49) | PTPN1GSK3BCYP3A4ALDH1A1DHODH | |
| SCHEMBL27870931 | 0.81 | SMN1; SMN2 (0.50) | PTPN1GSK3BCYP3A4ALDH1A1DHODH | |
| SCHEMBL30354087 | 0.81 | PTPN1 (0.67) | PTPN1GSK3BCYP3A4ALDH1A1TRPA1 | |
| SCHEMBL8766718 | 0.81 | PTPN1 (0.67) | PTPN1GSK3BCYP3A4ALDH1A1TRPA1 | |
| SCHEMBL474016 | 0.80 | GSK3B (0.64) | GSK3BALDH1A1TRPA1MAPK1HIF1A | |
| SCHEMBL6339905 | 0.79 | LCK (0.58) | PTPN1GSK3BALDH1A1TRPA1MAPK1 | |
| SCHEMBL203740 | 0.79 | CYP2A6 (0.46) | PTPN1CYP3A4ALDH1A1DHODHCYP2A6 | |
| SCHEMBL30389099 | 0.78 | CYP3A4 (0.57) | CYP3A4DHODHHPGDLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017021270-A1 | PROCESS FOR THE SYNTHESIS OF RAVIDASVIR | HC-PHARMA AG (CH) | 2017-02-09 | — | — | WO | disclosed |
| EP-2797913-B1 | QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-17 | — | — | EP | disclosed |
| EP-2797913-B1 | QUINAZOLINONE DERIVATIVES AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-17 | — | — | EP | disclosed |
| US-9382261-B2 | Substituted quinazolinones as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-07-05 | — | — | US | disclosed |
| US-9382261-B2 | Substituted quinazolinones as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-07-05 | — | — | US | disclosed |
| US-9382261-B2 | Substituted quinazolinones as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-07-05 | — | — | US | disclosed |
| US-20150203474-A1 | SOLID FORMS COMPRISING INHIBITORS OF HCV NS5A, COMPOSITIONS THEREOF, AND USES THEREWITH | PRESIDIO PHARMACEUTICALS, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150203474-A1 | SOLID FORMS COMPRISING INHIBITORS OF HCV NS5A, COMPOSITIONS THEREOF, AND USES THEREWITH | PRESIDIO PHARMACEUTICALS, INC. | 2015-07-23 | — | — | US | disclosed |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2011156543-A2 | INHIBITORS OF HCV NS5A PROTEIN | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156543-A2 | INHIBITORS OF HCV NS5A PROTEIN | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2373172-A1 | INHIBITORS OF HCV NS5A | Presidio Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065674-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065674-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PTPN1 202/4885GSK3B 493/4885CYP3A4 2538/4885 |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PTPN1 202/4885GSK3B 493/4885CYP3A4 2538/4885 |
| US-20150203474-A1 | SOLID FORMS COMPRISING INHIBITORS OF HCV NS5A, COMPOSITIONS THEREOF, AND USES THEREWITH | ABL1, HAVCR2, MAVS | PTPN1 134/4885GSK3B 1341/4885CYP3A4 1531/4885 |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | PTPN1 202/4885GSK3B 493/4885CYP3A4 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.